{
    "xml": "<topic id=\"PHP1466\" outputclass=\"drug\" rev=\"1.11\" type=\"drug\" namespace=\"/drugs/danaparoid-sodium\" basename=\"danaparoid-sodium\" title=\"DANAPAROID SODIUM\">\n<title>DANAPAROID SODIUM</title>\n<body>\r\n<p outputclass=\"interactionsLinks\"> List of individual interactants: <xref format=\"dita\" href=\"#bnf_int_1313\" namespace=\"/interactions/list-of-drug-interactions/anticoagulants/danaparoid\">Danaparoid</xref>\n</p>\n<data name=\"vtmid\">108992003</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_668507728\" title=\"Heparinoids\">Heparinoids</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">  </data>\n</data>\r\n</body>\n<topic id=\"PHP58949\" outputclass=\"indicationsAndDose\" rev=\"1.39\" parent=\"/drugs/danaparoid-sodium\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Prevention of deep-vein thrombosis in general or orthopaedic surgery</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By subcutaneous injection</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>750&#8239;units twice daily for 7&#8211;10 days, initiate treatment before operation, with last pre-operative dose 1&#8211;4 hours before surgery.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Thromboembolic disease in patients with history of heparin-induced thrombocytopenia</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">Initially by intravenous injection</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult (body-weight up to 55 kg)</p>\n<p>Initially 1250&#8239;units, then (by continuous intravenous infusion) 400&#8239;units/hour for 2 hours, then (by continuous intravenous infusion) 300&#8239;units/hour for 2 hours, then (by continuous intravenous infusion) 200&#8239;units/hour for 5 days.</p>\n</li>\n<li outputclass=\"patientGroup adult\">\n<p>Adult (body-weight 55&#8211;89 kg)</p>\n<p>Initially 2500&#8239;units, then (by continuous intravenous infusion) 400&#8239;units/hour for 2 hours, then (by continuous intravenous infusion) 300&#8239;units/hour for 2 hours, then (by continuous intravenous infusion) 200&#8239;units/hour for 5 days.</p>\n</li>\n<li outputclass=\"patientGroup adult\">\n<p>Adult (body-weight 90 kg and above)</p>\n<p>Initially 3750&#8239;units, then (by continuous intravenous infusion) 400&#8239;units/hour for 2 hours, then (by continuous intravenous infusion) 300&#8239;units/hour for 2 hours, then (by continuous intravenous infusion) 200&#8239;units/hour for 5 days.</p>\n</li>\n</ul>\n</section>\n</body>\n</topic>\n<topic id=\"PHP59099\" outputclass=\"contraindications\" rev=\"1.10\" parent=\"/drugs/danaparoid-sodium\">\n<title>Contra-indications</title>\n<body>\n<section outputclass=\"contraindications\">\n<p>\n<ph outputclass=\"contraindication\">Active peptic ulcer (unless this is the reason for operation)</ph>; <ph outputclass=\"contraindication\">acute bacterial endocarditis</ph>; <ph outputclass=\"contraindication\">diabetic retinopathy</ph>; <ph outputclass=\"contraindication\">epidural anaesthesia (with treatment doses)</ph>; <ph outputclass=\"contraindication\">haemophilia and other haemorrhagic disorders</ph>; <ph outputclass=\"contraindication\">recent cerebral haemorrhage</ph>; <ph outputclass=\"contraindication\">severe hypertension</ph>; <ph outputclass=\"contraindication\">spinal anaesthesia (with treatment doses)</ph>; <ph outputclass=\"contraindication\">thrombocytopenia (unless patient has heparin-induced thrombocytopenia)</ph>\n</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP59137\" outputclass=\"cautions\" rev=\"1.10\" parent=\"/drugs/danaparoid-sodium\">\n<title>Cautions</title>\n<body>\n<section outputclass=\"cautions\">\n<p>\n<ph outputclass=\"caution\">Antibodies to heparins (risk of antibody-induced thrombocytopenia)</ph>; <ph outputclass=\"caution\">body-weight over 90&#8239;kg</ph>; <ph outputclass=\"caution\">recent bleeding</ph>; <ph outputclass=\"caution\">risk of bleeding</ph>\n</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP58944\" outputclass=\"interactions\" rev=\"1.16\" parent=\"/drugs/danaparoid-sodium\">\n<title>Interactions</title>\n<body>\n<section outputclass=\"general\">\n<sectiondiv>\n<p>Appendix 1 (danaparoid).</p>\n<p>Caution with concomitant use of drugs that increase risk of bleeding.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP58892\" outputclass=\"sideEffects\" rev=\"1.9\" parent=\"/drugs/danaparoid-sodium\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"generalSideEffects\">\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"notKnown\">\n<p outputclass=\"title\">Frequency not known</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Bleeding</ph>; <ph outputclass=\"sideEffect\">hypersensitivity reactions</ph>; <ph outputclass=\"sideEffect\">rash</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP58933\" outputclass=\"pregnancy\" parent=\"/drugs/danaparoid-sodium\">\n<title>Pregnancy</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Manufacturer advises avoid&#8212;limited information available but not known to be harmful.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP59160\" outputclass=\"breastFeeding\" parent=\"/drugs/danaparoid-sodium\">\n<title>Breast feeding</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Amount probably too small to be harmful but manufacturer advises avoid.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP59032\" outputclass=\"hepaticImpairment\" parent=\"/drugs/danaparoid-sodium\">\n<title>Hepatic impairment</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Caution in moderate impairment (increased risk of bleeding).</p>\n<p>Avoid in severe impairment unless patient has heparin-induced thrombocytopenia and no alternative available.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP58908\" outputclass=\"renalImpairment\" parent=\"/drugs/danaparoid-sodium\">\n<title>Renal impairment</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Use with caution in moderate impairment.</p>\n<p>Avoid in severe impairment unless patient has heparin-induced thrombocytopenia and no alternative available.</p>\n</sectiondiv>\n</section>\n<section outputclass=\"additionalMonitoringInRenalImpairment\">\n<sectiondiv>\n<p>Increased risk of bleeding in renal impairment, monitor anti-Factor Xa activity.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP58825\" outputclass=\"monitoringRequirements\" parent=\"/drugs/danaparoid-sodium\">\n<title>Monitoring requirements</title>\n<body>\n<section outputclass=\"monitoringOfPatientParameters\">\n<sectiondiv>\n<p>Monitor anti factor Xa activity in patients with body-weight over 90&#8239;kg.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP59207\" outputclass=\"directionsForAdministration\" rev=\"1.8\" parent=\"/drugs/danaparoid-sodium\">\n<title>Directions for administration</title>\n<body>\n<section>\n<sectiondiv>\n<p outputclass=\"specificity\">With <ph outputclass=\"route\">intravenous</ph> use</p>\n<p>For <i>intravenous infusion</i> (<i>Orgaran</i>\n<tm tmtype=\"reg\"/>), give continuously in Glucose 5% or Sodium chloride 0.9%.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP1466-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/danaparoid-sodium\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP77403\" title=\"Solution for injection\" namespace=\"/drugs/danaparoid-sodium/solution-for-injection\">Solution for injection</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78413\" namespace=\"/treatment-summaries/parenteral-anticoagulants\" title=\"Parenteral anticoagulants\" count=\"1\" rel=\"backlink\">Parenteral anticoagulants</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"interaction\" href=\"#bnf_int_1313\" namespace=\"/interactions/list-of-drug-interactions/anticoagulants/danaparoid\" title=\"Danaparoid\" count=\"1\" rel=\"link\">Danaparoid</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP77403\" namespace=\"/drugs/danaparoid-sodium/solution-for-injection\" title=\"Solution for injection\" count=\"1\" rel=\"link\">Solution for injection</xref>\n</links>\n</topic>",
    "id": "PHP1466",
    "outputclass": "drug",
    "rev": "1.11",
    "type": "drug",
    "namespace": "/drugs/danaparoid-sodium",
    "basename": "danaparoid-sodium",
    "title": "DANAPAROID SODIUM",
    "interactants": [
        {
            "id": "bnf_int_1313",
            "label": "Danaparoid"
        }
    ],
    "vtmid": "108992003",
    "drugClassification": [
        "Heparinoids"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Prevention of deep-vein thrombosis in general or orthopaedic surgery",
                        "html": "Prevention of deep-vein thrombosis in general or orthopaedic surgery"
                    }
                ],
                "specificity": {
                    "routes": [
                        "subcutaneous injection"
                    ],
                    "textContent": "By subcutaneous injection",
                    "html": "By subcutaneous injection"
                },
                "adult": [
                    {
                        "textContent": "750 units twice daily for 7&#8211;10 days, initiate treatment before operation, with last pre-operative dose 1&#8211;4 hours before surgery.",
                        "html": "<p>750&#8239;units twice daily for 7&#8211;10 days, initiate treatment before operation, with last pre-operative dose 1&#8211;4 hours before surgery.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Thromboembolic disease in patients with history of heparin-induced thrombocytopenia",
                        "html": "Thromboembolic disease in patients with history of heparin-induced thrombocytopenia"
                    }
                ],
                "specificity": {
                    "routes": [
                        "Initially intravenous injection"
                    ],
                    "textContent": "Initially by intravenous injection",
                    "html": "Initially by intravenous injection"
                },
                "adult": [
                    {
                        "textContent": "Initially 1250 units, then (by continuous intravenous infusion) 400 units/hour for 2 hours, then (by continuous intravenous infusion) 300 units/hour for 2 hours, then (by continuous intravenous infusion) 200 units/hour for 5 days.",
                        "html": "<p>Initially 1250&#8239;units, then (by continuous intravenous infusion) 400&#8239;units/hour for 2 hours, then (by continuous intravenous infusion) 300&#8239;units/hour for 2 hours, then (by continuous intravenous infusion) 200&#8239;units/hour for 5 days.</p>",
                        "ageGroup": "(body-weight up to 55 kg)"
                    },
                    {
                        "textContent": "Initially 2500 units, then (by continuous intravenous infusion) 400 units/hour for 2 hours, then (by continuous intravenous infusion) 300 units/hour for 2 hours, then (by continuous intravenous infusion) 200 units/hour for 5 days.",
                        "html": "<p>Initially 2500&#8239;units, then (by continuous intravenous infusion) 400&#8239;units/hour for 2 hours, then (by continuous intravenous infusion) 300&#8239;units/hour for 2 hours, then (by continuous intravenous infusion) 200&#8239;units/hour for 5 days.</p>",
                        "ageGroup": "(body-weight 55&#8211;89 kg)"
                    },
                    {
                        "textContent": "Initially 3750 units, then (by continuous intravenous infusion) 400 units/hour for 2 hours, then (by continuous intravenous infusion) 300 units/hour for 2 hours, then (by continuous intravenous infusion) 200 units/hour for 5 days.",
                        "html": "<p>Initially 3750&#8239;units, then (by continuous intravenous infusion) 400&#8239;units/hour for 2 hours, then (by continuous intravenous infusion) 300&#8239;units/hour for 2 hours, then (by continuous intravenous infusion) 200&#8239;units/hour for 5 days.</p>",
                        "ageGroup": "(body-weight 90 kg and above)"
                    }
                ]
            }
        ]
    },
    "contraindications": {
        "contraindications": [
            {
                "type": "contraindications",
                "textContent": "Active peptic ulcer (unless this is the reason for operation)",
                "html": "Active peptic ulcer (unless this is the reason for operation)"
            },
            {
                "type": "contraindications",
                "textContent": "acute bacterial endocarditis",
                "html": "acute bacterial endocarditis"
            },
            {
                "type": "contraindications",
                "textContent": "diabetic retinopathy",
                "html": "diabetic retinopathy"
            },
            {
                "type": "contraindications",
                "textContent": "epidural anaesthesia (with treatment doses)",
                "html": "epidural anaesthesia (with treatment doses)"
            },
            {
                "type": "contraindications",
                "textContent": "haemophilia and other haemorrhagic disorders",
                "html": "haemophilia and other haemorrhagic disorders"
            },
            {
                "type": "contraindications",
                "textContent": "recent cerebral haemorrhage",
                "html": "recent cerebral haemorrhage"
            },
            {
                "type": "contraindications",
                "textContent": "severe hypertension",
                "html": "severe hypertension"
            },
            {
                "type": "contraindications",
                "textContent": "spinal anaesthesia (with treatment doses)",
                "html": "spinal anaesthesia (with treatment doses)"
            },
            {
                "type": "contraindications",
                "textContent": "thrombocytopenia (unless patient has heparin-induced thrombocytopenia)",
                "html": "thrombocytopenia (unless patient has heparin-induced thrombocytopenia)"
            }
        ]
    },
    "cautions": {
        "cautions": [
            {
                "type": "cautions",
                "textContent": "Antibodies to heparins (risk of antibody-induced thrombocytopenia)",
                "html": "Antibodies to heparins (risk of antibody-induced thrombocytopenia)"
            },
            {
                "type": "cautions",
                "textContent": "body-weight over 90 kg",
                "html": "body-weight over 90&#8239;kg"
            },
            {
                "type": "cautions",
                "textContent": "recent bleeding",
                "html": "recent bleeding"
            },
            {
                "type": "cautions",
                "textContent": "risk of bleeding",
                "html": "risk of bleeding"
            }
        ]
    },
    "interactions": {
        "general": [
            {
                "type": "general",
                "textContent": "Appendix 1 (danaparoid).\n\nCaution with concomitant use of drugs that increase risk of bleeding.",
                "html": "<p>Appendix 1 (danaparoid).</p><p>Caution with concomitant use of drugs that increase risk of bleeding.</p>"
            }
        ]
    },
    "sideEffects": {
        "general": {
            "frequencies": {
                "notKnown": [
                    {
                        "type": "notKnown",
                        "textContent": "Bleeding",
                        "html": "Bleeding",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "hypersensitivity reactions",
                        "html": "hypersensitivity reactions",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "rash",
                        "html": "rash",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    }
                ]
            }
        }
    },
    "pregnancy": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Manufacturer advises avoid&#8212;limited information available but not known to be harmful.",
                "html": "<p>Manufacturer advises avoid&#8212;limited information available but not known to be harmful.</p>"
            }
        ]
    },
    "breastFeeding": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Amount probably too small to be harmful but manufacturer advises avoid.",
                "html": "<p>Amount probably too small to be harmful but manufacturer advises avoid.</p>"
            }
        ]
    },
    "hepaticImpairment": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Caution in moderate impairment (increased risk of bleeding).\n\nAvoid in severe impairment unless patient has heparin-induced thrombocytopenia and no alternative available.",
                "html": "<p>Caution in moderate impairment (increased risk of bleeding).</p><p>Avoid in severe impairment unless patient has heparin-induced thrombocytopenia and no alternative available.</p>"
            }
        ]
    },
    "renalImpairment": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Use with caution in moderate impairment.\n\nAvoid in severe impairment unless patient has heparin-induced thrombocytopenia and no alternative available.",
                "html": "<p>Use with caution in moderate impairment.</p><p>Avoid in severe impairment unless patient has heparin-induced thrombocytopenia and no alternative available.</p>"
            }
        ],
        "additionalMonitoring": [
            {
                "type": "additionalMonitoring",
                "textContent": "Increased risk of bleeding in renal impairment, monitor anti-Factor Xa activity.",
                "html": "<p>Increased risk of bleeding in renal impairment, monitor anti-Factor Xa activity.</p>"
            }
        ]
    },
    "monitoringRequirements": {
        "patientParameters": [
            {
                "type": "patientParameters",
                "textContent": "Monitor anti factor Xa activity in patients with body-weight over 90 kg.",
                "html": "<p>Monitor anti factor Xa activity in patients with body-weight over 90&#8239;kg.</p>"
            }
        ]
    },
    "directionsForAdministration": {
        "directionsForAdministration": [
            {
                "type": "directionsForAdministration",
                "specificity": {
                    "textContent": "With intravenous use",
                    "html": "With <ph outputclass=\"route\">intravenous</ph> use",
                    "routes": [
                        "intravenous"
                    ]
                },
                "textContent": "For intravenous infusion (Orgaran ), give continuously in Glucose 5% or Sodium chloride 0.9%.",
                "html": "<p>For <i>intravenous infusion</i> (<i>Orgaran</i>\n<tm tmtype=\"reg\"/>), give continuously in Glucose 5% or Sodium chloride 0.9%.</p>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ]
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP77403",
                "label": "Solution for injection",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ],
        "treatmentSummary": [
            {
                "id": "PHP78413",
                "label": "Parenteral anticoagulants",
                "type": "treatmentSummary"
            }
        ]
    },
    "links": {
        "interaction": [
            {
                "id": "bnf_int_1313",
                "label": "Danaparoid",
                "type": "interaction"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP77403",
                "label": "Solution for injection",
                "type": "medicinalForm"
            }
        ]
    }
}